Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.
Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.
复制标题
DOI：
10.1002/cpph.2
复制
发表时间：
2016-06-01
影响因子：
--
通讯作者：
Beatty GL
中科院分区：
文献类型：
--
作者：
Lee JW;Komar CA;Bengsch F;Graham K;Beatty GL
胰腺导管腺癌（PDAC）在美国癌症相关死亡中排名第四，对于无法切除的疾病患者，目前治疗选择有限，缺乏治愈潜力。PDAC的临床前小鼠模型概括了人类胰腺癌的生物学，为合理开发可能改善患者预后的新治疗方法提供了机会。随着最近对实体恶性肿瘤患者亚群的免疫治疗的成功，人们对如何利用免疫治疗治疗PDAC的兴趣越来越大。在这里，我们讨论了遗传小鼠模型在PDAC免疫生物学方面的价值，并描述了它们在研究新型免疫疗法方面的应用。此外，我们提出了这些模型的几种变体，可用于药物开发，并告知疾病生物学和治疗反应性的独特方面。
Pancreatic ductal adenocarcinoma (PDAC) ranks fourth among cancer-related deaths in the United States and for patients with unresectable disease, treatment options are currently limited and lack curative potential. Preclinical mouse models of PDAC that recapitulate the biology of human pancreatic cancer offer an opportunity for the rational development of novel treatment approaches that may improve patient outcomes. With the recent success of immunotherapy for subsets of patients with solid malignancies, interest is mounting regarding how to utilize immunotherapy for the treatment of PDAC. Here, we discuss the value of genetic mouse models for informing the immunobiology of PDAC and describe their application for investigating novel immunotherapeutics. In addition, we present several variants of these models, which may be used in drug development and to inform unique aspects of disease biology and therapeutic responsiveness.